

Examiner-Initiated Interview Summary	Application No.	Applicant(s)	
	10/023,584	Rosen et al.	
	Examiner	Art Unit	
	Gary L. Kunz	1647	

All Participants:

Status of Application: 041

(1) Gary L. Kunz.

(3) _____.

(2) Melissa Pytel.

(4) _____.

Date of Interview: 12 April 2004

Time: 10:30

Type of Interview:

- ☒ Telephonic
☐ Video Conference
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☒ No
 If Yes, provide a brief description:

Part I.

Rejection(s) discussed:
None

Claims discussed:
all pending claims 1 - 110

Prior art documents discussed:
None

Part II.

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:
See Continuation Sheet

Part III.

- ☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.
☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

Gary L. Kunz
(Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: Ms. Pytel requested that in the restriction mailed 7/24/03 Group I (claims 1-19 and 22-50) be recombined with Group III (claims 52-66, 69-89 and 97-110) since these claims are all directed to antibodies or binding fragments thereof of VEGF-2. Additionally, Ms. Pytel requested that the restriction among the various fragments of VEGF-2 be withdrawn. Upon further consideration of the restriction requirement mailed 7/24/03, Groups I and III will be recombined. Additionally, the restriction requirement among the fragments of VEGF-2 will be withdrawn.